EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations — EATON

Bronchial Neoplasms Clinical Trial

Official title:
An Open-label, Multicenter, Phase I Dose-escalation Trial of EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and Acquired EGFR p.T790M-positive Resistance to 1st or 2nd Generation EGFR TKI Therapy Remark: According to Version V02_0 of the Protocol, Patients May Also be Eligible if EGFR TKI-treatment naïve, EGFR p.T790M-negative at Progression While on EGFR TKI Therapy or After Progression While on Osimertinib Treatment

Status Completed

Clinical Trial Summary

The aim of this trial is to identify the maximum tolerated dose (MTD)/recommended phase II dose (RP2D), to define pharmacokinetic (PK) parameters and the preliminary efficacy of a continuous treatment with EGF816 and trametinib in locally advanced or metastatic (stage IIIB or IV) lung cancer patients with activating mutations in the epithelial growth factor receptor (EGFR).

Clinical Trial Description

The population of interest for this trial is defined by patients with non-small cell lung cancer (NSCLC) harbouring the sensitizing EGFR mutations del19 or p.L858R. Patients may be enrolled in first- or later lines of therapy and independently of the prior (approved) EGFR inhibitor administered and independently of the EGFR p.T790M-status. Those individuals whose tumors harbour high-level amplifications of MET or other EGFR mutations except for del19, p.L858R or p.T790M will be excluded from the trial. The molecular status must have been determined in a biopsy collected at progression to the last systemic and prior to the initiation of the trial treatment The aim of the trial is to identify the maximum tolerated dose (MTD)/recommended phase II dose (RP2D) for a continuous treatment with the 3rd generation EGFR inhibitor EGF816 and the MEK inhibitor trametinib. The recommendations for dose level escalations will be based on an "up-and-down" design proposed by Storer, 1989. The dose limiting toxicity (DLT) period comprises the first 28 days of treatment with EGF816 and trametinib at the designated dose level (Cycle 1). PK parameters of the combination treatment will be assessed for every dose level in every patient during the dose-escalation part. Preliminary efficacy of EGF816 and trametinib in the trial population will be assessed by RECIST (v1.1) analysis of scheduled CT scans (every 8 weeks or as clinically indicated. Throughout the study blood samples will be collected to monitor cell free plasma DNA (cfDNA). Patients who develop resistance upon treatment with the study drugs will undergo a rebiopsy to identify potential mechanisms of resistance. ;

Study Design

Related Conditions & MeSH terms

Bronchial Neoplasms

Clinical Trial Details

NCT number	NCT03516214
Study type	Interventional
Source	University of Cologne
Contact
Status	Completed
Phase	Phase 1
Start date	April 25, 2018
Completion date	November 27, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02909452` - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT02493023` - Automatic CT-to-patient Registration During Navigated Bronchoscopy and EBUS	N/A
Terminated	`NCT02050724` - ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT	Phase 2
Suspended	`NCT03745859` - Evaluation of a New Open Source Virtual Bronchoscope Navigation System
Terminated	`NCT04644315` - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors	Phase 2
Recruiting	`NCT02804100` - Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients	N/A
Active, not recruiting	`NCT05241873` - (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	Phase 1/Phase 2
Completed	`NCT03037385` - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT04862780` - (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	Phase 1/Phase 2
Not yet recruiting	`NCT06376084` - Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Recruiting	`NCT03402048` - The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial	Phase 3
Recruiting	`NCT02264210` - Icotinib for Completed Resected IB NSCLC With EGFR Mutation	Phase 2
Terminated	`NCT05153408` - (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC	Phase 1
Completed	`NCT01261585` - Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT	N/A
Recruiting	`NCT06177925` - A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC	Phase 2
Completed	`NCT02897778` - Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors	Phase 1
Completed	`NCT02745002` - Navigated EBUS and Functional Imaging in Lung Cancer	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.